Niraparib

5 · 20 / page

Ask MedXY AI

Latest news

Tag

newsNiraparibovarian cancer

Real-world Evidence: Managing Platelet Counts in Ovarian Cancer Patients on First-Line Maintenance Niraparib

By MedXY|May 8, 2026

A US cohort study of 543 ovarian cancer patients revealed 37% experienced decreased platelets during niraparib maintenance. Onset typically occurred within 1 month but resolved rapidly with dose adjustments, resulting in low discontinuation

FDA Greenlights Niraparib–Abiraterone–Prednisone for BRCA2‑Mutated Metastatic Castration‑Sensitive Prostate Cancer: Implications and Practical Considerations

newsBRCA2Niraparib

Niraparib

Latest news

Real-world Evidence: Managing Platelet Counts in Ovarian Cancer Patients on First-Line Maintenance Niraparib

FDA Greenlights Niraparib–Abiraterone–Prednisone for BRCA2‑Mutated Metastatic Castration‑Sensitive Prostate Cancer: Implications and Practical Considerations

Niraparib Plus Abiraterone Significantly Improves rPFS in HRR‑Deficient mCSPC: AMPLITUDE Phase 3 Results

MAGNITUDE final analyses: Niraparib + Abiraterone improves symptoms and delays chemotherapy but not overall survival in HRR‑altered mCRPC

Comprehensive Overview of the AMPLITUDE Trial Results on Niraparib and AAP in HRR-Deficient Prostate Cancer